TCI Wealth Advisors’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-231
Closed -$2.84K 1709
2023
Q1
$2.84K Buy
+231
New +$3.76K ﹤0.01% 1875

Other funds holding PRME

TCI Wealth Advisors's PRME Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Prime Medicine (PRME) in Q2 2023, closing a stake of 231 shares — an estimated $2.84K sold.

TCI Wealth Advisors first reported a position in PRME in Q1 2023 and held it in 1 quarter. The position peaked at $2.84K in Q1 2023. 79 funds tracked by Wall St. Rank hold PRME as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Prime Medicine position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 231 Prime Medicine shares in Q2 2023, an estimated $2.84K.
  • TCI Wealth Advisors first reported a position in Prime Medicine in Q1 2023 and held it in 1 quarter.
  • TCI Wealth Advisors's Prime Medicine position peaked at $2.84K in Q1 2023.
  • 79 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.